MX2017008633A - Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas. - Google Patents
Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas.Info
- Publication number
- MX2017008633A MX2017008633A MX2017008633A MX2017008633A MX2017008633A MX 2017008633 A MX2017008633 A MX 2017008633A MX 2017008633 A MX2017008633 A MX 2017008633A MX 2017008633 A MX2017008633 A MX 2017008633A MX 2017008633 A MX2017008633 A MX 2017008633A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion protein
- tnfr
- peak
- hydrophobic chromatography
- hydrophobic
- Prior art date
Links
- 108010008165 Etanercept Proteins 0.000 title abstract 7
- 238000004519 manufacturing process Methods 0.000 title abstract 6
- 239000012535 impurity Substances 0.000 title 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 8
- 238000004587 chromatography analysis Methods 0.000 abstract 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 abstract 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 abstract 3
- 235000011130 ammonium sulphate Nutrition 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000011780 sodium chloride Substances 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011067 equilibration Methods 0.000 abstract 1
- 229960000403 etanercept Drugs 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 239000012616 hydrophobic interaction chromatography medium Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052938 sodium sulfate Inorganic materials 0.000 abstract 1
- 235000011152 sodium sulphate Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
La presente invención se refiere a un procedimiento para preparar una mezcla de proteína de fusión TNFR-Fc que comprende un contenido objetivo de pico 3 de cromatografía hidrofóbica, y a un procedimiento para ajustar un contenido de pico 3 de cromatografía hidrofóbica. Específicamente, la presente invención se refiere (a) a un procedimiento para preparar una mezcla de proteína de fusión TNFR-Fc usando un medio de cromatografía de interacción hidrofóbica que contiene un grupo funcional aromático, que está pre-equilibrado con un tampón de equilibrio que comprende cloruro de sodio o sulfato de amonio, y una muestra que comprende una mezcla líquida de proteína de fusión TNFR-Fc producida a partir de células de mamífero, y a un procedimiento para ajustar el contenido de pico 3 de cromatografía hidrofóbica por cromatografía hidrofóbica usando un tampón de equilibrio que contiene una concentración predeterminada de cloruro de sodio o de sulfato de amonio. La presente invención puede proporcionar un procedimiento para preparar una proteína de fusión TNFR-Fc usando en la producción de la proteína de fusión TNFR-Fc cromatografía hidrofóbica, realizando cromatografía hidrofóbica mediante la equilibración usando un tampón de equilibrio que contiene una concentración predeterminada de cloruro de sodio o de sulfato de amonio, de ese modo ajustando el contenido de pico 3 de cromatografía hidrofóbica para contener un contenido objetivo de pico 3 de cromatograma hidrofóbico. Por lo tanto, el procedimiento presentado anteriormente puede ser usado favorablemente en la fabricación de medicamentos biológicos que comprenden una proteína recombinante, tal como etanercept producido a partir de cultivos de células animales, mediante tecnología genética recombinante.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140195766 | 2014-12-31 | ||
| PCT/KR2015/014393 WO2016108569A1 (ko) | 2014-12-31 | 2015-12-29 | 목적하는 함량으로 불순물을 포함하는 tnfr-fc 융합 단백질의 제조방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017008633A true MX2017008633A (es) | 2018-04-26 |
| MX394035B MX394035B (es) | 2025-03-21 |
Family
ID=56284628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017008633A MX394035B (es) | 2014-12-31 | 2015-12-29 | Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10988527B2 (es) |
| EP (1) | EP3241849A4 (es) |
| JP (2) | JP6793996B2 (es) |
| KR (1) | KR102018608B1 (es) |
| AU (1) | AU2015372801B2 (es) |
| BR (1) | BR112017014224A2 (es) |
| IL (1) | IL253218B (es) |
| MX (1) | MX394035B (es) |
| RU (1) | RU2670166C1 (es) |
| SA (1) | SA517381861B1 (es) |
| WO (1) | WO2016108569A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11952399B2 (en) * | 2018-12-18 | 2024-04-09 | Amgen Inc. | Methods for purifying proteins |
| WO2023053032A1 (en) * | 2021-09-28 | 2023-04-06 | Kashiv Biosciences, Llc | An improved process for purification of fusion protein |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7294481B1 (en) * | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| US20080230478A1 (en) * | 2005-05-24 | 2008-09-25 | Ge Healthcare Bio-Sciences Ab | Regeneration Of A Chromatography Matrix |
| EP2114984A2 (en) | 2007-01-17 | 2009-11-11 | Merck Serono S.A. | Process for the purification of fc-containing proteins |
| US9284347B2 (en) * | 2010-01-22 | 2016-03-15 | Boehringer Ingelheim International Gmbh | Chromatographic method for purifying FC-containing proteins |
| CN102382190B (zh) | 2010-09-01 | 2014-04-09 | 山东新时代药业有限公司 | 分离和去除TNFR-Fc融合蛋白中寡聚体的方法 |
| US20130330340A1 (en) | 2011-02-25 | 2013-12-12 | Stephen R. Hamilton | Production of n- and o-sialylated tnfrii-fc fusion protein in yeast |
| WO2012176158A1 (en) * | 2011-06-24 | 2012-12-27 | Dr. Reddy's Laboratories Limited | Purification of chimeric protein |
| AU2012282960A1 (en) * | 2011-07-08 | 2014-01-16 | Merck Sharp & Dohme Corp. | Method for purifying Fc-fusion protein |
| ES2651483T3 (es) | 2011-08-17 | 2018-01-26 | Ares Trading S.A. | Método para preparar la forma activa de la proteína de fusión TNRF-Fc |
| US9302002B2 (en) | 2011-10-18 | 2016-04-05 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with combinations of sugars and polyols |
| PL2895188T3 (pl) * | 2012-09-11 | 2018-06-29 | Coherus Biosciences, Inc. | Prawidłowo pofałdowany etanercept o wysokiej czystości i doskonałej wydajności |
| WO2014102814A1 (en) | 2012-12-31 | 2014-07-03 | Intas Biopharmaceuticals Limited | Process for the purification of fc fusion proteins |
-
2015
- 2015-12-29 US US15/541,111 patent/US10988527B2/en active Active
- 2015-12-29 KR KR1020150188455A patent/KR102018608B1/ko active Active
- 2015-12-29 RU RU2017124181A patent/RU2670166C1/ru active
- 2015-12-29 JP JP2017535373A patent/JP6793996B2/ja active Active
- 2015-12-29 EP EP15875663.5A patent/EP3241849A4/en active Pending
- 2015-12-29 IL IL253218A patent/IL253218B/en unknown
- 2015-12-29 BR BR112017014224-4A patent/BR112017014224A2/pt not_active Application Discontinuation
- 2015-12-29 MX MX2017008633A patent/MX394035B/es unknown
- 2015-12-29 WO PCT/KR2015/014393 patent/WO2016108569A1/ko not_active Ceased
- 2015-12-29 AU AU2015372801A patent/AU2015372801B2/en active Active
-
2017
- 2017-07-04 SA SA517381861A patent/SA517381861B1/ar unknown
-
2019
- 2019-07-10 JP JP2019128325A patent/JP2019172702A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015372801A1 (en) | 2017-07-20 |
| KR102018608B1 (ko) | 2019-09-06 |
| EP3241849A1 (en) | 2017-11-08 |
| NZ733388A (en) | 2018-11-30 |
| IL253218A0 (en) | 2017-08-31 |
| RU2670166C1 (ru) | 2018-10-18 |
| US10988527B2 (en) | 2021-04-27 |
| SA517381861B1 (ar) | 2021-09-08 |
| EP3241849A4 (en) | 2018-06-20 |
| WO2016108569A1 (ko) | 2016-07-07 |
| MX394035B (es) | 2025-03-21 |
| JP2018503630A (ja) | 2018-02-08 |
| JP2019172702A (ja) | 2019-10-10 |
| JP6793996B2 (ja) | 2020-12-02 |
| US20170369553A1 (en) | 2017-12-28 |
| IL253218B (en) | 2022-08-01 |
| BR112017014224A2 (pt) | 2018-03-06 |
| AU2015372801B2 (en) | 2018-12-20 |
| KR20160081827A (ko) | 2016-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124871A2 (es) | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes | |
| EA201690600A1 (ru) | Метаболически оптимизированная клеточная культура | |
| BR112018002214A2 (pt) | ?métodos para cultivar células e para produzir uma proteína, meios de cultura de células cho e de batelada alimentada e/ou alimentação, e, alimentação de cultura de células cho? | |
| MX2021000210A (es) | Metodos y productos para transfeccion de celulas. | |
| MX2018015414A (es) | Terapia de célula t adoptiva mejorada. | |
| HRP20191409T1 (hr) | Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula | |
| MX388092B (es) | Metodos mejorados para la modificacion de acido nucleicos diana. | |
| MX2020003798A (es) | Metodos para la purificacion de arilsulfatasa a. | |
| BR112016015678A2 (pt) | Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso | |
| EA201492177A1 (ru) | Очистка идуронат-2-сульфатазы | |
| AR103172A1 (es) | Reducción selectiva de residuos de cisteina en anticuerpos il-17 | |
| MX383558B (es) | Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco | |
| AR086200A1 (es) | Hongos filamentosos que tienen un fenotipo de viscosidad alterado | |
| JP2016513478A5 (es) | ||
| EA202190736A1 (ru) | Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью | |
| BR112014003841A2 (pt) | estratégia de múltiplas cópias para produção em alto título e alta pureza de proteínas de múltiplas subunidades tal como anticorpos em micróbios transformados tal como pichia pastoris | |
| EA202091349A1 (ru) | Способы культивирования клеток | |
| AR097805A1 (es) | Células de cambio de temperatura para la expresión de alto rendimiento de polipéptidos en levadura y otros transformados | |
| BR112018000168A2 (pt) | método para produção de células ips de alta qualidade | |
| MX2017008633A (es) | Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas. | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| MX2015010887A (es) | Formulaciones y metodos para aumentar la produccion de proteinas recombinantes. | |
| BR112017024089A2 (pt) | métodos para produção de uma proteína recombinante em uma célula hospedeira, para liberação de proteína recombinante expressada por uma cultura de célula hospedeira, para redução da viscosidade de uma cultura celular que expressa uma proteína recombinante, para aumento da concentração extracelular de uma proteína recombinante expressada pela cultura celular e para redução do período de tempo para cultivo de uma cultura celular que expressa uma proteína recombinante, composição farmacêutica, e, uso de pei. | |
| MX2023005172A (es) | Distribucion de casquetes de cisteina modificados. | |
| TH171389A (th) | วิธีการสำหรับการเตรียมโปรตีนหลอมรวม tnfr-fc (tnfr-fc fusion protein) ที่ประกอบด้วยปริมาณเป้าหมายของสิ่งปนเปื้อน |